{
    "2018-12-02": [
        [
            {
                "time": "2018-03-15",
                "original_text": "High-cost Gilead cell therapy proves durable for some lymphoma patients",
                "features": {
                    "keywords": [
                        "Gilead",
                        "cell therapy",
                        "durable",
                        "lymphoma"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "Novartis Drug Revolade Improves Outcomes For ITP Patients",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Revolade",
                        "ITP",
                        "Improves"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}